The European Medicines Agency's CHMP adopted a positive opinion on 17 September 2026 recommending EU marketing authorisation for Sepalna (senaparib), a PARP inhibitor discovered by Shanghai-based IMPACT Therapeutics, as maintenance therapy for advanced ovarian, fallopian tube or primary peritoneal cancer. The opinion is a recommendation, not a final approval — the European Commission still has to rule, typically within about 67 days. It is also the first EU regulatory step for a drug IMPACT already sells at home: senaparib has been approved and reimbursed in China since early 2025, and IMPACT licensed the European rights to specialty pharma company Pharmanovia in a deal worth up to €423.5 million two months before this opinion.
Sepalna's case, in four figures
Trial and deal figures from IMPACT Therapeutics' and Pharmanovia's own disclosures and EMA's published CHMP record.
Sixty-six countries, one licensing deal
IMPACT Therapeutics discovered and developed senaparib, but it will not be the one selling it in Europe. On 30 July 2026, IMPACT signed an exclusive licensing agreement granting Pharmanovia, a UK-based specialty pharma company that acquires and relaunches branded medicines, the rights to manufacture, develop and commercialize senaparib across 66 countries: all 27 EU member states, the UK, Norway, Iceland, Switzerland and Liechtenstein, Australia, New Zealand and a set of Middle East and North Africa markets. The deal is worth up to €423.5 million in upfront payment plus regulatory and commercial milestones, with tiered royalties reported in the mid-20s percent on net sales. This CHMP opinion, less than two months after the deal signed, is the first concrete regulatory progress toward Pharmanovia actually being able to sell the drug it licensed.
A PARP inhibitor field already worth billions
$7.20B → $13.02B
Global PARP inhibitor market, 2024 actual to 2031 forecast, per Coherent Market Insights (2024).
Sources: Coherent Market Insights, PARP Inhibitor Market Size and Share Report · Fortune Business Insights, Ovarian Cancer Therapeutics Market Size, Share & COVID-19 Impact Analysis
Regulatory News outlook
Senaparib arrives in a PARP inhibitor field four incumbents already share, and an EU approval alone won't move that much revenue — Pharmanovia will need to win prescribing share from drugs oncologists already know. At an illustrative 5% share of Coherent Market Insights' 2031 global PARP inhibitor forecast, senaparib's EU opportunity would sit in the range of $650 million a year at the category's full maturity, well behind the market leaders it would be competing against.
How we got here: 5% of Coherent Market Insights' $13.02 billion 2031 global PARP inhibitor forecast is roughly $651 million, an illustrative upper-bound estimate for one late entrant's global share, not an EU-specific or company-specific projection.
Sepalna against Europe's established PARP inhibitors
| Drug | Maker | EU maintenance-setting status |
|---|---|---|
| Sepalna / senaparib (IMPACT Therapeutics) | IMPACT Therapeutics; EU rights licensed to Pharmanovia | CHMP positive opinion, Sep 2026; EC decision pending |
| Lynparza (olaparib) | AstraZeneca / Merck | Approved as 1L maintenance monotherapy in BRCA-mutated disease, and with bevacizumab in HRD-positive disease |
| Zejula (niraparib) | GSK | Approved as 1L maintenance monotherapy regardless of biomarker status — the first all-comers PARP monotherapy |
| Rubraca (rucaparib) | Originally Clovis Oncology, restructured after its 2022 bankruptcy | Maintenance-setting authorisation remains active; a later-line, BRCA-mutant indication was withdrawn in 2022 |
From each company's own labelling and EMA's public record; not a clinical comparison.
A PARP inhibitor already reimbursed in China
Senaparib is a PARP1/2 inhibitor — it blocks an enzyme cancer cells rely on to repair their own DNA, causing cells with certain existing DNA-repair defects to die. IMPACT discovered and developed it independently, then co-developed the China market through a joint venture with Junshi Biosciences. China's National Medical Products Administration approved it there, under the trade name Paishuning, in January 2025, for the same first-line ovarian cancer maintenance indication now before EU regulators; it was added to China's National Reimbursement Drug List in December 2025. That approval is the commercial track record IMPACT brings to this CHMP opinion: senaparib is not a new, unproven molecule asking Europe to go first — it already has a year and a half of real-world use in one major market behind it.
Three things senaparib brings to a crowded field
A large, clear trial win
The pivotal FLAMES Phase 3 trial showed a 57% reduction in the risk of progression or death versus placebo (HR 0.43, 95% CI 0.32–0.58), with median PFS not reached for senaparib against 13.6 months for placebo, consistent across BRCA-mutated and BRCA-negative patients.
A market already proven, elsewhere
Unlike a first-in-class asset seeking its first approval anywhere, senaparib has been on the market and reimbursed in China since early 2025 — real prescribing history, not just trial data, to point to.
A partner that already sells to Europe
Pharmanovia's business is specifically relaunching and commercializing licensed medicines across more than 160 countries; IMPACT doesn't need to build its own European sales infrastructure to benefit from this opinion.
What CHMP actually recommended on 17 September
CHMP's opinion covers Sepalna 20 mg hard capsules as maintenance treatment for adult patients with advanced (FIGO stage III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after finishing first-line platinum-based chemotherapy — an all-comers indication not restricted to patients with BRCA mutations or other biomarkers. In the FLAMES trial behind that recommendation, senaparib's 12-month progression-free survival rate was 72.2% against 53.7% for placebo, widening to 63.0% versus 31.3% at 24 months. The trade-off is a heavier side-effect burden than placebo, as is typical for this drug class: grade 3 or higher adverse events occurred in 66.3% of senaparib patients versus 20.3% on placebo, most commonly anemia, thrombocytopenia and neutropenia, with dose interruptions in three-quarters of senaparib patients. No press release from IMPACT Therapeutics or Pharmanovia reacting specifically to the CHMP opinion could be found for this article; EMA's own published record and independent trade coverage from OnCLive are this article's primary sources for the opinion itself.
“It is our great pleasure to share with you the successful approval of Senaparib for the Chinese market, which is another strong proof of the excellence of IMPACT's in-house synthetic lethality research and development platform and the R&D execution team.” Dr. Sui Xiong Cai, Chief Executive Officer, IMPACT Therapeutics — on senaparib's January 2025 China approval, not this CHMP opinion; no executive statement reacting to the CHMP opinion specifically could be found for this article
From Shanghai to a Hong Kong debut
Senaparib's road from discovery to a second regulator
- 2009
IMPACT Therapeutics founded
Founded in Shanghai, China to develop synthetic-lethality-based precision cancer therapies.
- 2023
FLAMES data first presented
Phase 3 topline data for senaparib as ovarian cancer maintenance therapy presented at ESMO.
- January 2025
China approval
NMPA approves senaparib (Paishuning) as first-line maintenance therapy for advanced ovarian cancer, co-developed in China via a joint venture with Junshi Biosciences.
- August 2025
EU filing accepted
EMA formally accepts the Marketing Authorisation Application for senaparib.
- December 2025
China reimbursement
Senaparib added to China's National Reimbursement Drug List.
- 13 May 2026
Hong Kong IPO
IMPACT Therapeutics lists on HKEX (7630), raising roughly HK$844 million; shares reportedly doubled on debut.
- 30 July 2026
Pharmanovia licensing deal
IMPACT licenses EU, UK, Swiss, Australian and New Zealand rights to senaparib to Pharmanovia for up to €423.5 million.
- 17 September 2026
CHMP positive opinion
CHMP recommends EU marketing authorisation for Sepalna (senaparib).
- Ahead
European Commission decision
A final EC decision typically follows a CHMP opinion within about 67 days, though no company-stated date for this case was found.
The distance between an opinion and a decision
A few gaps are worth stating plainly. Neither IMPACT Therapeutics nor Pharmanovia appears to have issued its own press release reacting specifically to the CHMP opinion, at least not one this newsroom's research tools could locate — the strongest sourcing available is EMA's own published record plus independent trade coverage, which is a real but thinner footing than a Spotlight built on a company's own announcement. IMPACT's exact current CEO title also carries some public ambiguity, with both a Group-level chief executive and a separately titled “President & CEO, IMPACT Therapeutics China” appearing in different interviews; this article uses the title as it appears on IMPACT's own January 2025 approval statement. And a CHMP positive opinion is a recommendation, not a marketing authorisation — the European Commission's own decision, expected within roughly two months on the usual centralized-procedure timeline, is still to come.
Sources & further reading
- European Medicines Agency, CHMP meeting highlights and Sepalna (senaparib) opinion record, 17 September 2026. ema.europa.eu
- OnCLive, “EU Approval Recommended by CHMP for Senaparib in Advanced Ovarian Cancer,” 18 September 2026. onclive.com
- BioSpace, “IMPACT Therapeutics Signs Exclusive License Agreement With Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand,” 30 July 2026. biospace.com
- European Biotechnology, “Pharmanovia licenses China-approved PARP drug for up to €423.5m.” european-biotechnology.com
- Cooley, coverage of IMPACT Therapeutics' HK$844 million Hong Kong IPO, 13 May 2026. cooley.com
- ESMO, FLAMES Phase 3 trial abstract, senaparib maintenance in newly diagnosed advanced ovarian cancer. oncologypro.esmo.org
- Coherent Market Insights, PARP Inhibitor Market Size and Share Report. biospace.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did CHMP recommend for Sepalna?
On 17 September 2026, the EU's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for Sepalna (senaparib) as maintenance treatment for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in patients who responded to first-line platinum-based chemotherapy. A CHMP positive opinion is a recommendation; the European Commission still has to issue a final decision, typically within about 67 days.
Who will sell Sepalna in Europe?
Pharmanovia, a UK-based specialty pharmaceutical company, holds exclusive rights to manufacture, develop and commercialize senaparib across 66 countries including the EU, UK, Switzerland, Australia and New Zealand, under a licensing deal signed with IMPACT Therapeutics around 30 July 2026 worth up to €423.5 million plus royalties.
Is senaparib approved anywhere already?
Yes. China's National Medical Products Administration approved senaparib, sold there as Paishuning, in January 2025 as first-line maintenance therapy for the same ovarian cancer indication, and it was added to China's National Reimbursement Drug List in December 2025.
Is IMPACT Therapeutics publicly traded?
Yes. IMPACT Therapeutics listed on the Hong Kong Stock Exchange (HKEX: 7630) on 13 May 2026, raising roughly HK$844 million, with its Hong Kong retail tranche reported oversubscribed more than 2,284 times.
